Abstract
Cathelicidins are a class of antimicrobial peptides (AMPs) that are part of the first line of defense of the innate immune system. While cathelicidin-derived peptides such as LL-37 can be directly bactericidal, Streptococcus pyogenes (Spy; Group A Streptococcus) is highly resistant to killing. Furthermore, Spy detects LL-37 through the CovRS two-component system to regulate its virulence factors. One effect of this signaling is the repression of expression of the bacterial protease SpeB. Prior work has also shown that SpeB, along with other bacterial proteases can cleave LL-37. However, it is unclear if SpeB cleavage of LL-37 impacts antimicrobial function and CovRS signaling activity. Using a genetic approach, we show that the presence SpeB did not significantly impact the killing of Spy by LL-37 relative to other known resistance factors. Furthermore, while SpeB cleaves LL-37, CovRS maintains sensitivity to LL-37 fragments. These results indicate that SpeB cleavage of LL-37 does not negatively impact virulence factor regulation in Spy.
Keywords: Streptococcus pyogenes, invasive infection, cathelicidin, LL-37, antimicrobial peptide, virulence factor, protease, gene regulation
Introduction
Antimicrobial peptides (AMPs) are a conserved component of innate immune response and play a critical role in defense against pathogens. Defensins and cathelicidins are the main classes of AMPs in mammals. Humans express both ∂ and ß-defensins, whereas hCAP-18 is the sole member of the cathelicidin family1. hCAP-18 is induced during infection and injury in epithelial cells and is constitutively expressed in lymphocytes1,2. It is most studied for its direct antimicrobial action, but it also has significant signaling activity that stimulates wound repair and immune defense by promoting immune cell recruitment and differentiation, epithelial cell migration, chemokine production, and neutrophil extracellular traps (NETs) formation2–5. hCAP-18 is largely inert until proteolytic removal of an amino-terminal prodomain – canonically, this occurs via neutrophil proteinase 3 or keratinocyte kallikrein 5/73,6. Proteinase 3 cleavage generates the well-studied active peptide LL-37. However, biologically active peptides of varying alternate lengths, resulting from cleavage by other proteases, have been widely observed7,8. Several microbes are described to cleave LL-37 further and are thought to destroy its antimicrobial activity to allow the bacterium to evade immune killing9,10.
One of the microbes with the potential to cleave LL-37 is Streptococcus pyogenes (Spy; Group A Streptococcus)9,10. This human-restricted bacterium is responsible for over half a million annual deaths worldwide through infections such as pharyngitis and impetigo, or develop into severe disease, including life-threatening Streptococcal toxic shock syndrome (STSS), scarlet fever, and necrotizing fasciitis, and their immune-mediated sequela11. Numerous virulence factors are important for the pathogenesis of these diseases, and most are regulated by the LL-37-sensing two-component system CovRS (control of virulence; also known as CsrRS)12–15. Intrinsically, using LL-37 as a signal for virulence regulation requires external sensing to survive exposure. Accordingly, Spy is resistant to physiological levels of LL-37 through several mechanisms, such as modifying its cell wall charge to decrease electrostatic attraction of the charged peptide and sequestration away from the cell envelope via the major surface-anchored virulence factor, M protein16,17. The secreted protease SpeB degrades numerous host molecules, including LL-37, which contributes to immune evasion and pathogenesis18. While other bacterial proteases inhibit LL-37-mediated killing, it is unclear if SpeB activity contributes to LL-37 resistance10. CovRS is expected to repress SpeB expression in the presence of LL-3714, making the relevance of SpeB in LL-37 resistance, and the impacts of SpeB on CovRS regulation, uncertain.
In this work, we sought to test this model by which the action of SpeB on LL-37 can impact Spy killing and gene regulation, including speB autoregulation (Fig. 1). Relative to other described resistance factors, the contribution of SpeB to resisting killing by LL-37 was undetectable. Consistent with prior findings, LL-37 repressed SpeB expression in vitro and induced CovRS-mediated signaling. Mutation or inhibition of SpeB did not significantly impact CovRS responsiveness to LL-37. In part, the extreme sensitivity of CovRS to LL-37 could help ensure function even as a portion of the LL-37 pool is degraded. However, SpeB cleavage is also primarily targeted to regions of LL-37 not involved in CovRS binding, potentially leaving the core signaling molecule intact. Together, these findings detail how Spy integrates potentially conflicting pathways to regulate virulence factors needed to subvert the immune response directed against it.
Figure 1. CovRS-SpeB regulatory circuit schematic.

Response regulator, CovR, is phosphorylated (CovR~P) by histidine kinase, CovS, resulting in speB derepression. In the presence of LL-37, CovR is dephosphorylated by CovS phosphatase. This results in speB repression. LL-37 can be subject to SpeB proteolytic cleavage, and potentially block CovRS signaling through the cathelicidin peptide.
Results
Spy is resistant to LL-37 killing at physiological levels.
To determine whether SpeB contributed to LL-37 resistance, wild type and mutant Spy strains were grown in the presence of LL-37. Spy mutant for the cell wall modification enzyme, D-alanine-D-alanine protein ligase (ΔdltA), the surface M protein (Δemm), and capsule hyaluronate synthase (ΔhasA), were included as controls, since all are known to contribute to LL-37 resistance16,22,23. Indeed, all had a reduced LL-37 MIC compared to wild type (Fig. 2A). Notably, though the protease SpeB has been shown to cleave LL-3710,24, the MIC of LL-37 was unaltered for a ΔspeB strain (Fig. 2A). To further examine killing by LL-37, we compared the rate of survival between wild type and ΔspeB in the presence of LL-37. After 2 h of exposure, there was no significant difference in survival between the two strains (Fig. 2B). Altogether, this suggests that even if SpeB cleaves LL-37, this activity is not necessary to confer resistance to LL-37.
Fig. 2. Spy is resistant to LL-37 killing at physiological levels.

(A) Minimal Inhibitory Concentration of LL-37 (μg/mL) in Spy strains. (B) Rate of Spy survival before and after LL-37 (16 μg/mL) exposure at MIC over 0, 1, and 2 h. Wild type (black) and ΔspeB (gray). Statistical significance was determined using a one-way ANOVA with Dunnett’s multiple comparisons test. ****P<0.0001, **P<0.01, ns: not significant.
LL-37 can prevent SpeB activation.
LL-37 has the potential to repress speB through CovRS. Since it is a substrate of SpeB, there is potential for SpeB to relieve its own repression10,14. LL-37 at 300 nM (1.35 μg/mL) is physiologically relevant and commonly used to study CovRS regulation13,14,25. This concentration is below the MIC (Fig. 2A) for Spy and did not suppress bacterial growth (Fig. 3A). Using an internally quenched peptide sensitive to SpeB cleavage, sub10321, Spy grown in the presence of subinhibitory levels of LL-37 had reduced SpeB activity (Fig. 3B). Therefore, LL-37 is sufficient to prevent the production of SpeB.
Figure 3. CovRS is sensitive to LL-37 signaling below inhibitory concentrations.

(A) Spy grown in the presence of LL-37 (300 nM; 1.35 μg/mL). (A) Spy growth curve in treated and untreated conditions. (B) SpeB activity assay in overnight Spy sample grown in treated and untreated conditions measured through an internally quenched reporter peptide.
Impact of SpeB on CovRS signaling.
To better understand CovRS signaling, we used a validated transcriptional reporter that is sensitive to CovRS signaling19. The fluorescent reporter contains transcriptional fusion of gfp with the speB promoter, which is repressed by dephosphorylated CovR, and rfp with the hasABC promoter, which is induced by dephosphorylated CovR (Fig. 1)26,27. During in vitro growth, GFP (speB) is induced during late log phase, and this was repressed by LL-37 (Fig. 4A), consistent with protease activity measures (Fig. 3B). Even in the absence of LL-37, ΔspeB had reduced expression of GFP (speB), consistent with recently described autoregulation through Vfr19. The RFP (hasABC) construct was induced by LL-37 in both wild-type and ΔspeB Spy, consistent with previous observations19 (Fig. 4A). The ΔspeB strain expressed a small but significant increase in RFP (hasABC) over wild-type, but this was observed in both the presence and absence of LL-37. To better understand these dynamics, we used flow cytometry to quantify this at the single-cell level, using a similar gating strategy as previously19 (Fig. 4B). As expected, Spy grown with LL-37 had a population shift positive for RFP, and these populations were identical for both wild-type and ΔspeB strains. However, there was significant heterogeneity even in these induced conditions, with the ΔspeB strain maintaining populations of intermediate and low hasABC expression. Lastly, we confirmed these results with E-64, a potent SpeB inhibitor29. Wild-type Spy containing the dual reporter was grown in the presence of titrations of LL-37; LL-37 repressed GFP (speB) and induced RFP (hasABC) in a dose-dependent manner (Fig. 4C). Expression of the hasABC promoter (RFP) remained unaffected by E-64 inhibition of SpeB. The impact of E-64 on expression of speB (GFP) is expected from recently described autoregulation through the sensor Vfr9. Altogether, these results suggest that impairing SpeB activity, through genetic mutants and activity inhibition, has little effect on the CovRS response to LL-37.
Fig. 4. LL-37 controls CovRS signaling in the WT and ΔspeB.

Wild-type and ΔspeB were treated with LL-37 (300 nM). CovRS inducibility was detected through fluorescent PspeB::gfp (GFP) and PhasA::rfp reporter (RFP). (A) Measurement of fluorescence over bacterial density after 15 h of growth. (B) Flow cytometry demonstrating hasABC expression (RFP; horizontal axis) and bacterial cell count (vertical axis) at stationary phase of live Spy populations. (C) Wild-type Spy was grown with LL-37 (0 – 300 nM) and E-64 (0 – 200 μM) for 15 h. Expression of speB (blue, left) and hasABC (orange, right) were detected. Statistical significance was determined using a one-way ANOVA with Dunnett’s multiple comparisons test. ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05, ns: not significant.
LL-37 fragments still induce CovRS.
SpeB degrades many antimicrobials and has the potential to inactivate LL-37 through proteolytic degradation30. To map the regions where SpeB could cleave LL-37, we designed internally quenched peptides tessellating the length of LL-37 (Fig. 5A). Upon incubation with SpeB, cath39, cath35, and cath11, corresponding to the regions of LL-37 proximal to the carboxy and amino termini, were readily cleaved. These data indicate SpeB actively cleaves several regions of LL-37, consistent with early observations. However, most LL-37-derived peptides were resistant to cleavage. Notably, these internal regions (corresponding to cath31, cath27, cath23, cath19, cath15) correspond to the region of LL-37 detected by CovRS25. Further, truncated forms of LL-37 corresponding to these cleavage products repressed GFP (speB) (Fig. 5B) and induced RFP (hasABC) (Fig. 5C). This suggests that, even after cleavage by SpeB, LL-37 and cleavage products can maintain CovRS stimulating activity.
Fig. 5. LL-37 fragments still induce CovRS.

(A) AlphaFold structure of LL-37 and mapping of LL-37 cleavage by SpeB. SpeB (0.2 μg/mL) was incubated with internally quenched LL-37 fragments. Cleavage was detected by fluorescence (RFU) of the internally quenched peptides. (B and C) Wild type (gray) and ΔspeB (blue) were grown in the presence of LL-37, and LL-37 fragments (IG-25, RI-19, and VP-06; 300 nM). CovRS inducibility was detected through fluorescent PspeB::gfp (GFP; B) and PhasABC::rfp reporter (RFP; C). Statistical significance was determined using a one-way ANOVA with Dunnett’s multiple comparisons test. ****P<0.0001, ***P<0.001, **P<0.01, ns: not significant.
Discussion
Slightly larger or small variants of LL-37 can be generated by the action of different host proteases on hCAP18, maintaining antimicrobial and immune signaling activities31, but Spy can cleave LL-37 into yet smaller fragments. Our results show that SpeB does not substantially confer resistance to LL-37 or alter LL-37-dependent CovRS signaling for Spy. Although SpeB can cleave LL-37, deletion or pharmacologic inhibition of SpeB had little effect on LL-37 activity. Consequently, LL-37 retained the capacity to repress transcription of speB and induce hasABC. Together, these results indicate that LL-37 remains an effective CovRS signaling molecule even after SpeB processing, allowing Spy to maintain virulence regulation while encountering host antimicrobial peptides.
AMPs play a protective role and are a first line of defense during infections. Within healthy skin, LL-37 remains low, but upon injury, inflammatory processes induce neutrophil degranulation and active LL-37 levels rise32,33. In addition to their antimicrobial roles, LL-37 (and possibly similar peptides derived from hCAP18) are involved in immune regulation including in the recruitment and activation of immune cells, and stimulating wound healing, broadly activities that could be important during Spy skin infections2,34. Thus, while SpeB cleavage of LL-37 does not greatly impact Spy resistance or gene regulation, it has the potential to contribute to microbial virulence through these other activities. This would be informed by future studies that map whether specific regions of LL-37 mediate these activities, and if they would be destroyed by SpeB proteolysis. Additionally, there could be benefits to engineered variants of LL-37 with antimicrobial and immune regulatory activities, but that removes sensing by CovRS.
LL-37 is an effective antimicrobial against many bacteria. The contribution of SpeB to LL-37 resistance is possibly limited due to the extensive repertoire of established resistance mechanisms for Spy. On the surface, M protein sequesters hCAP18/LL-37 to neutralize toxicity, while teichoic acid modifications can repel the peptide from reaching the bacterial surface22,23. Further, the hyaluronic acid capsule also provides a protective role in LL-37 killing23. Interestingly, these do not appear to be entirely functionally redundant, since a decreased MIC is seen for all of them. Together, these may additively contribute to the high-level resistance and possibly, in a strain lacking these, a measure of SpeB-dependent LL-37 resistance observed. Notably, this is seen for several bacterial pathogens that resist LL-37 by degrading the peptide10. For example, the skin pathogen Staphylococcus aureus degrades LL-37 through major metalloprotease, aureolysin, and confers resistance to killing9. Conversely, Spy grown in subinhibitory levels of LL-37 coordinate regulation of virulence factor through CovRS, while also inhibiting speB expression13. Thus, the antimicrobial capacities of LL-37 and SpeB mediated resistance is negligible.
During infections, it would be advantageous for a pathogen to titrate the amount of a virulence factors, such as inflammatory SpeB, to avoid rapid immune clearance. However, when sufficient SpeB is available to degrade LL-37, still SpeB does not inhibit CovRS signaling. CovRS modulates nearly 15% of the genome, including most major virulence factors14. While CovRS mutations can arise in invasive infections and have improved resistance to neutrophil clearance, these mutants are unable to transmit within the population due to attenuated growth, colonization, and adhesion35,36. Potentially, it is advantageous for Spy to not cleave LL-37 further if it would destroy the ability to detect it by CovS. Altogether, this suggests that maintaining CovRS sensitivity and fine-tuning virulence factor expression is crucial for transmission and pathogenesis alike. A better understanding of how Spy and other pathogens integrate host immune signals into virulence regulation may reveal opportunities to therapeutically disrupt signaling pathways that drive disease progression without imposing strong selective pressure for antibiotic resistance.
Methods
Bacterial strains and growth conditions:
All strains are described in Table 1. Spy strains were grown in Todd Hewitt broth with 5% yeast (THY) at 37°C with 5% CO2. Bacterial aliquots were washed in PBS and resuspended in PBS with 20% glycerol for storage at −80°C and grown fresh for each experiment.
Table 1:
Strain List
LL-37 killing assays:
Spy grown overnight statically at 37°C were diluted 1:40 into Todd-Hewitt media and grown at 37°C to OD600 0.400. 2×105 bacteria washed in cold PBS were diluted into serum-free DMEM containing phenol red and 5% THY and titrations of LL-37 (GeneScript) and incubated at 37°C with 5% CO2. Dilutions were plated at indicated intervals for time-kill experiments, or the minimum antimicrobial concentration (MIC) was recorded as the dilution that prevented observable growth after 18 h incubation.
Fluorescence reporter measurements:
Spy 5448 strains grown in Todd-Hewitt Broth with 5% yeast (THY) to mid-exponential phase were used to inoculate fresh, phenol red-free RPMI supplemented with THY (5%) and erythromycin (2 μg/mL) in a 96-well black, clear-bottom plate (Costar). Bacteria were grown with or without supplementation of LL-37 (GeneScript), LL-37 truncations (GeneScript; IG-25, RI-19 and VP-06) and/or E-64 (Sigma Aldrich) at indicated concentrations. Cultures were grown for 15 h at 37 °C and 5% CO2 with measurements of absorbance (600 nm), GFP (ex. 479 nm, em. 520 nm), and RFP (ex. 579 nm, em. 616 nm) using a BioTek Synergy H1 plate reader. Expression of speB and hasABC were analyzed by fluorescence of GFP or RFP over absorbance. For flow cytometry experiments, bacterial sample processing was completed as previously19. Briefly, all samples were pelleted and washed with PBS with 1 mM EDTA. To identify live bacteria, samples were stained using BactoView™ Dead 760/780 (Biotium cat. 40113). Samples were strained through a 100 μm filter (Avantor) and fixed. To identify Spy, samples were incubated with goat anti-Group A Carbohydrate (GAC) antibody (Fitzgerald 70-XG70_R) and rabbit anti-goat APC (Invitrogen A56570). Samples were analyzed using BD FACSymphony A3 with excitation lasers: PE-594-A, APC, APC-Cy7. Appropriate single-color controls were used for compensation. Data was analyzed using FlowJo, RRID:SCR_008520.
Protein Modeling and Cleavage Prediction:
The structure of LL-37 was modeled in AlphaFold Server v3 and visualized in PyMOL. Potential SpeB cleavage sites were predicted as previously described20 based on known targets using ScanProsite (Expasy). Search of the motif [IVFYM]-[ADEGKSTN] also included net negative charge sidechain charge in the P1’-P5’ region.
Protease activity:
SpeB activity within bacterial supernatants was detected with the fluorescent peptide sub103, internally quenched with an N-terminal Mca and the C-terminal Lys-Dnp (CPC Scientific), as previously21. Briefly, 10 μM of peptide was incubated in PBS with 2 mM dithiothreitol assay buffer with 10 μL of supernatant at 37°C for 30 minutes in triplicates. Victor Nivo plate reader (PerkinElmer) measured fluorescence every 30 sec (ex. 323 nm, em. 398 nm). Measurements of SpeB cleavage of LL-37 truncations was performed with internally-quenched FRET peptides cath39 [LLGDFFR], cath35 [GDFFRKSKE], cath31 [RKSKEKIGK], cath27 [EKIGKEFKR], cath23 [KEFKRIVQ], cath19 [RIVQRIKDF], cath15 [RIKDFLRNL], and cath11 [FLRNLVPRT] in PBS, 1 mM CaCl2, 0.01% Tween-20 (Sigma P7949). After 1 hour incubation at 37°C, the proteolysis was measured using the Victor Nivo plate reader with fluorophore excitation at 323 nm and emission at 398 nm.
Statistics:
GraphPad Prism, RRID:SCR_002798, was used to evaluate statistical significance. Unless otherwise stated, one-way ANOVA with Dunnett’s multiple comparisons test was used for the statistical analysis of experiments and P values < 0.05 were considered significant.
Supplementary Material
Supplemental Figure Legend
Fig. S1. Spy WT and ΔspeB growth curves. (A) Spy wild type and ΔspeB grown in the presence of LL-37, IG-25, RI-19, or VP-06 (300 nM).
Acknowledgements
We thank Victor Nizet for strains and members of LaRock lab for helpful discussions. This work was supported in part by the Emory Flow Cytometry Core (EFCC) Facility (RRID:SCR_023536). This work was supported by the National Institute of Allergy and Infectious Diseases of the NIH under award numbers AI153071 (C.N.L.) and AI180089 (C.N.L.), training grants AI106699 (S.G.), AI179103 (S.G.), a Synergy award from Emory University (C.N.L.), and a Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease award (C.N.L.). The content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health.
Footnotes
Declaration of interests
The authors declare no competing interests.
Resource Availability
Lead contact.
Requests for further information and resources should be directed to and will be fulfilled by the lead contact, Christopher LaRock (christopher.larock@emory.edu)
Materials availability.
All unique reagents generated in this study are available from the lead contact upon completion of a material transfer agreement.
Data and code availability.
This study did not generate any original sequence data or code. Any additional information required to reanalyze the data reported in this study is available from the lead contact upon request.
References
- 1.Dorschner R. A. et al. Cutaneous Injury Induces the Release of Cathelicidin Anti-Microbial Peptides Active Against Group A Streptococcus. Journal of Investigative Dermatology 117, 91–97 (2001). [DOI] [PubMed] [Google Scholar]
- 2.Kahlenberg J. M. & Kaplan M. J. Little Peptide, Big Effects: The Role of LL-37 in Inflammation and Autoimmune Disease. The Journal of Immunology 191, 4895–4901 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Sørensen O., Arnljots K., Cowland J. B., Bainton D. F. & Borregaard N. The Human Antibacterial Cathelicidin, hCAP-18, Is Synthesized in Myelocytes and Metamyelocytes and Localized to Specific Granules in Neutrophils. Blood 90, 2796–2803 (1997). [PubMed] [Google Scholar]
- 4.Neumann A. et al. Novel Role of the Antimicrobial Peptide LL-37 in the Protection of Neutrophil Extracellular Traps against Degradation by Bacterial Nucleases. J Innate Immun 6, 860–868 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Minns D. et al. The neutrophil antimicrobial peptide cathelicidin promotes Th17 differentiation. Nat Commun 12, 1285 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Yamasaki K. et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. The FASEB Journal 20, 2068–2080 (2006). [DOI] [PubMed] [Google Scholar]
- 7.Sørensen O. E. et al. Wound Healing and Expression of Antimicrobial Peptides/Polypeptides in Human Keratinocytes, a Consequence of Common Growth Factors. The Journal of Immunology 170, 5583–5589 (2003). [DOI] [PubMed] [Google Scholar]
- 8.Yamasaki K. et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 13, 975–980 (2007). [DOI] [PubMed] [Google Scholar]
- 9.Sieprawska-Lupa M. et al. Degradation of Human Antimicrobial Peptide LL-37 by Staphylococcus aureus -Derived Proteinases. Antimicrob Agents Chemother 48, 4673–4679 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Schmidtchen A., Frick I., Andersson E., Tapper H. & Björck L. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Molecular Microbiology 46, 157–168 (2002). [DOI] [PubMed] [Google Scholar]
- 11.Carapetis J. R., Steer A. C., Mulholland E. K. & Weber M. The global burden of group A streptococcal diseases. The Lancet Infectious Diseases 5, 685–694 (2005). [DOI] [PubMed] [Google Scholar]
- 12.Tran-Winkler H. J., Love J. F., Gryllos I. & Wessels M. R. Signal Transduction through CsrRS Confers an Invasive Phenotype in Group A Streptococcus. PLoS Pathog 7, e1002361 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Gryllos I. et al. Induction of group A Streptococcus virulence by a human antimicrobial peptide. Proc. Natl. Acad. Sci. U.S.A. 105, 16755–16760 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Finn M. B., Ramsey K. M., Dove S. L. & Wessels M. R. Identification of Group A Streptococcus Genes Directly Regulated by CsrRS and Novel Intermediate Regulators. mBio 12, e01642–21 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Misiakos E. P., Bagias G., Patapis P., Sotiropoulos D., Kanavidis P., & Machairas A. Current Concepts in the Management of Necrotizing Fasciitis. Front. Surg. 1, 36 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Lauth X. et al. M1 Protein Allows Group A Streptococcal Survival in Phagocyte Extracellular Traps through Cathelicidin Inhibition. J Innate Immun 1, 202–214 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.LaRock C. N. et al. Group A Streptococcal M1 Protein Sequesters Cathelicidin to Evade Innate Immune Killing. Cell Host & Microbe 18, 471–477 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Carroll R. K. & Musser J. M. From transcription to activation: how group A streptococcus, the flesh-eating pathogen, regulates SpeB cysteine protease production. Molecular Microbiology 81, 588–601 (2011). [DOI] [PubMed] [Google Scholar]
- 19.Guerra S., Dash A., LaRock D. L. & LaRock C. N. A protease-sensing circuit links neutrophil inflammation to virulence regulation in Streptococcus pyogenes. Preprint at 10.64898/2026.05.15.725401 (2026). [DOI] [Google Scholar]
- 20.Johnson A. F. et al. Proinflammatory synergy between protease and superantigen streptococcal pyogenic exotoxins. Infect Immun 93, e00405–24 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.LaRock D. L. et al. Group A Streptococcus induces GSDMA-dependent pyroptosis in keratinocytes. Nature 605, 527–531 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Kristian S. A. et al. d -Alanylation of Teichoic Acids Promotes Group A Streptococcus Antimicrobial Peptide Resistance, Neutrophil Survival, and Epithelial Cell Invasion. J Bacteriol 187, 6719–6725 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Cole J. N. et al. M Protein and Hyaluronic Acid Capsule Are Essential for In Vivo Selection of covRS Mutations Characteristic of Invasive Serotype M1T1 Group A Streptococcus. mBio 1, e00191–10 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Johansson L. et al. Cathelicidin LL-37 in Severe Streptococcus pyogenes Soft Tissue Infections in Humans. Infect Immun 76, 3399–3404 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Velarde J. J., Ashbaugh M. & Wessels M. R. The Human Antimicrobial Peptide LL-37 Binds Directly to CsrS, a Sensor Histidine Kinase of Group A Streptococcus, to Activate Expression of Virulence Factors. Journal of Biological Chemistry 289, 36315–36324 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Neely M. N., Lyon W. R., Runft D. L. & Caparon M. Role of RopB in Growth Phase Expression of the SpeB Cysteine Protease of Streptococcus pyogenes. J Bacteriol 185, 5166–5174 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Albertí S., Ashbaugh C. D. & Wessels M. R. Structure of the has operon promoter and regulation of hyaluronic acid capsule expression in group A Streptococcus. Molecular Microbiology 28, 343–353 (1998). [DOI] [PubMed] [Google Scholar]
- 28.Love J. F., Tran-Winkler H. J. & Wessels M. R. Vitamin D and the Human Antimicrobial Peptide LL-37 Enhance Group A Streptococcus Resistance to Killing by Human Cells. mBio 3, e00394–12 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.LaRock C. N., Todd J., LaRock D. L., Olson J., O'Donoghue A. J., Robertson A. A. B., Cooper M. A., Hoffman H. M., Nizet V. IL-1β is an innate immune sensor of microbial proteolysis. Sci. Immunol. 1, eaah3539 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Nyberg P., Rasmussen M. & Björck L. α2-Macroglobulin-Proteinase Complexes Protect Streptococcus pyogenes from Killing by the Antimicrobial Peptide LL-37. Journal of Biological Chemistry 279, 52820–52823 (2004). [DOI] [PubMed] [Google Scholar]
- 31.Voronko O. E., Khotina V. A., Kashirskikh D. A., Lee A. A. & Gasanov V. A. O. Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications. IJMS 26, 8103 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Murakami M. et al. Vesicular LL-37 Contributes to Inflammation of the Lesional Skin of Palmoplantar Pustulosis. PLoS ONE 9, e110677 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Duplantier A. J. & Van Hoek M. L. The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds. Front. Immunol. 4, (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Nizet V. et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414, 454–457 (2001). [DOI] [PubMed] [Google Scholar]
- 35.Hollands A. et al. Genetic Switch to Hypervirulence Reduces Colonization Phenotypes of the Globally Disseminated Group A Streptococcus M1T1 Clone. J INFECT DIS 202, 11–19 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Treviño J. et al. CovS Simultaneously Activates and Inhibits the CovR-Mediated Repression of Distinct Subsets of Group A Streptococcus Virulence Factor-Encoding Genes. Infect Immun 77, 3141–3149 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Aziz R. K. et al. Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB. Molecular Microbiology 51, 123–134 (2004). [DOI] [PubMed] [Google Scholar]
- 38.Kansal R. G., Nizet V., Jeng A., Chuang W.-J. & Kotb M. Selective Modulation of Superantigen-Ind Responses by Streptococcal Cysteine Prot. Journal of Infectious Diseases 187, 398–407 (2003). [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Lead contact.
Requests for further information and resources should be directed to and will be fulfilled by the lead contact, Christopher LaRock (christopher.larock@emory.edu)
Materials availability.
All unique reagents generated in this study are available from the lead contact upon completion of a material transfer agreement.
Data and code availability.
This study did not generate any original sequence data or code. Any additional information required to reanalyze the data reported in this study is available from the lead contact upon request.
This study did not generate any original sequence data or code. Any additional information required to reanalyze the data reported in this study is available from the lead contact upon request.
